Phase I-II RTOG Study (99-06) of Patients With Muscle-Invasive Bladder Cancer Undergoing Transurethral Surgery, Paclitaxel, Cisplatin, and Twice-daily Radiotherapy Followed by Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy

• Published in: Urology (Ridgewood, N.J.) Vol. 73; no. 4; pp. 833 - 837
• Main Authors: Kaufman, Donald S, Winter, Kathryn A, Shipley, William U, Heney, Niall M, Wallace, H. James, Toonkel, Leonard M, Zietman, Anthony L, Tanguay, Simon, Sandler, Howard M
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.04.2009; Elsevier
• Subjects: Antineoplastic Agents - therapeutic use; Biological and medical sciences; Chemotherapy, Adjuvant; Cisplatin - therapeutic use; Combined Modality Therapy; Cystectomy; Female; Humans; Male; Medical sciences; Middle Aged; Muscle, Smooth - pathology; Neoplasm Invasiveness; Nephrology. Urinary tract diseases; Paclitaxel - therapeutic use; Tumors of the urinary system; Urethra; Urinary Bladder Neoplasms - pathology; Urinary Bladder Neoplasms - radiotherapy; Urinary Bladder Neoplasms - therapy; Urinary system involvement in other diseases. Miscellaneous; Urinary tract. Prostate gland; Urologic Surgical Procedures - methods; Urology; Antineoplastic agent; Nephrology; Adjuvant treatment; Transurethral route; Urology; Daily; Urethra; Urinary bladder; Taxane derivatives; Surgery; Phase II trial; Paclitaxel; Muscle; Invasive cancer; Antimitotic; Platinum II Complexes; Human; Urinary system disease; Preservation; Urinary tract disease; Malignant tumor; Radiotherapy; Bladder cancer; Cisplatin; Alkylating agent; Chemotherapy; Cystectomy; Treatment; Urinary system; Phase I trial; Surgical approach; Bladder disease; Cancer

Objectives To evaluate the safety, tolerance, protocol completion rate, tumor response rate, and patient survival of chemoradiotherapy for patients with muscle-invasive operable bladder cancer. Methods After transurethral resection of the tumor in patients with Stage T2-T4a bladder cancer, twice-dai...